One Iron Street,
Boston , MA, 02210
Boston , MA, 02210
Summary
The fund seeks to replicate the total return performance of the benchmark index, before fees and expenses, by investing in companies in the United States.
The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.
Next, the research team invests significantly in the securities comprising t More
Webiste
Directors
Sep 12, 2023- Sandra G. Sponem
- Dwight D. Churchill
- Gunjan Chauhan
- Carolyn M. Clancy
- Carl G. Verboncoeur
- James E. Ross
- Clare S. Richer
- Kristi L. Rowsell
Chief Compliance Officer
- Brian Harris
Price
- $ 71.61 ( -4.37 )
-
Apr 10, 2025Last Close
- Net Assets
-
$7B
Feb 27, 2024
- 52-Week High/Low
- $104.2 - $69.8
- Expense Ratio
- -
Performance
YTD
0%
3 Year
-20.73%
5 Year
-14.17%
Best
48.39%
2013
Worst
-25.87%
2022
Company Name |
Holding |
| State Street Global Advisors | 7.46 % |
| Sarepta Therapeutics Inc | 3.31 % |
| United Therapeutics Corp | 2.98 % |
| Alnylam Pharmaceuticals Inc | 2.86 % |
| Gilead Sciences Inc | 2.84 % |
| Amgen Inc | 2.82 % |
| AbbVie Inc | 2.74 % |
| Regeneron Pharmaceuticals Inc | 2.73 % |
| Exact Sciences Corp | 2.72 % |
| Biogen Inc | 2.69 % |
| More | 2.69 % |
Documents
NAV
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| XBI | 0% | -0.4% | 7.6% | -25.9% | -20.5% | 48% | 32.6% | -15.3% | 43.8% | -15.5% | |
| S&P 500 | -8.3% | 23.3% | 24.2% | -19.4% | 27.3% | 16.2% | 28.9% | -6.2% | 19.4% | 9.5% |
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| q1 | 0% | 6.3% | -8.2% | -19.7% | -3.6% | -18.6% | 26.2% | 3.4% | 17.2% | -26.3% | ||||
| q2 | 0% | -2.4% | 9.2% | -17.4% | -0.2% | 44.6% | -3% | 13.6% | 11.5% | 4.8% | ||||
| q3 | 0% | 0% | -12.2% | 6.8% | -7.2% | -0.6% | -13.6% | -0.4% | 12.2% | 22.6% | ||||
| q4 | 0% | 0% | 26.4% | 4.6% | -10.9% | 26.5% | 24.7% | -24.1% | -3.5% | -10.7% |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 2024 | -2.1% | 12.6% | -3.6% | -10.8% | 5.1% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |